Dosage Sample Clauses
The Dosage clause defines the specific amount and frequency of a substance, typically medication, to be administered to a patient. It outlines the exact measurements, such as milligrams or milliliters, and the schedule for administration, like once daily or every six hours. This clause ensures that all parties understand the correct quantity and timing, minimizing the risk of underdosing or overdosing and promoting patient safety.
Dosage. Child 1 month to 18 years1: The licensed dosing schedule (children of 3 years and over#) for glycopyrronium is based on the weight of the child, starting with approximately 12.8 micrograms/kg per dose three times per day and increasing by the doses listed in the SPC every 7 days. Dose titration should be continued until efficacy is balanced with undesirable effects and amended up or down as appropriate, to a maximum individual dose of 64 micrograms/kg body weight glycopyrronium or 6 ml (1.9 mg glycopyrronium) three times a day, whichever is less. Following the dose titration period, the child's sialorrhoea should be monitored, in conjunction with the carer at no longer than 3 monthly intervals, to assess changes in efficacy and/or tolerability over time, and the dose adjusted accordingly. # Sialanar is not recommended in children below the age of 3 years since there is very limited data on the efficacy and safety of glycopyrronium in this age group Adult population - Sialanar® is indicated for the paediatric population only. There is limited clinical trial evidence on the use of glycopyrronium in the adult population with pathological drooling. Prescribers may consider the unlicensed use of Sialanar for the treatment of hypersalivation in this population following current evidence based guidance3,4 Dosing should be at ≥1 hour before or at least 2 hours after meals or at consistent times with respect to food intake. Avoid high fat food.
Dosage. The regulated articles must receive the minimum absorbed ionizing radiation dose specified in the PPQ Treatment Manual or in another approved treatment schedule.
Dosage. ● A valid prescription form, written in English that has been approved and countersigned by a suitably qualified and registered healthcare practitioner, who is authorised to prescribe the Products. ● Such other information as the Supplier reasonably requests from time to time.
1. Processing of Personal Data under this agreement shall be limited to such processing activities as the Supplier is reasonably required to undertake in connection with its performance under this agreement.
2. Personal Data will be collected and processed for the following Purpose:
2.1 to allow Patients to receive the Products; and
2.2 to allow the Supplier to provide the Customer with Royal Mail delivery references. This allows the Customer and Patients to track delivery progress via Royal Mail's online delivery tracker website (Internet - ▇▇▇▇▇://▇▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇/track-your-item#/).
3. The Nature of the processing will be:
3.1 collection, recording and storage;
3.2 structuring and filing including in an organised database;
3.3 access and retrieval; and
3.4 combination with other data.
4. The Duration of the processing under this agreement will be the term of this agreement, and such other period as the Supplier may reasonably require in connection with this agreement, as per clause 24 in IPA embedded in this Schedule 2.
Dosage. 17.1. Licensee agrees by using trademark AstraGin® that serving size of at least 25mg is incorporated per serving. Recommended Serving Size is 50mg.
17.2. Licensee agrees by using trademark ActiGin® that serving size of at least 25mg is incorporated per serving. Recommended Serving Size is 50mg.
17.3. Licensee agrees by using trademark InnoSlim® that serving size of at least 100mg is incorporated per serving. Recommended Serving Size is 200mg.
17.4. Licensee agrees by using trademark Acteolin™ that serving size of at least 100mg is incorporated per serving. Recommended Serving Size is 200mg.
Dosage. Ovex: 1 tablet. If re-infection occurs, a second dose can be taken after 14 days. Advice and Follow up: All other members of household over 2 years old should be treated simultaneously. Hygiene measures should be taken for 14 days after treatment: Wash hands and scrub nails first thing every morning, after using the toilet or changing nappies, and immediately before eating (even snacks) or preparing food Have a bath or wash around the anus each morning immediately on rising Keep fingernails short Change and wash underwear, nightwear, and bed linen the morning after treatment Vacuum all carpets and clean bathroom surfaces daily Wear clean underwear daily Children can wear cotton underwear at night to help prevent scratching or spreading eggs General Advice: Avoidance of re-infection = personal hygiene
Dosage. There is a marked variation in dose requirements for patients with myeloproliferative disease. The usual range is 500mg to 2g a day. In order to obtain a stable level of control patients often take different doses on different days to get the desired effect. The dose will be established and monitored by the Haematology Department. Hydroxycarbamide must always be prescribed and dispensed as 500mg capsules, either generic hydroxycarbamide 500mg capsules or Hydrea® 500mg capsules. Hydroxycarbamide tablets 100mg or 1g (Siklos®) are specifically licensed for the treatment of sickle cell disease only and must not be used for patients with myeloproliferative disease or CML (patient confusion and incorrect dosing has been reported). Generally, hydroxycarbamide is used to lower and manage initial high counts of abnormal cell lines. For example in essential thrombocythaemia, doses should be adjusted to maintain a platelet count of 200 – 400 x109/L without lowering WBC below 4 x 109/L. Hydroxycarbamide is usually taken in the mornings. It is possible to split the dose when the daily dose is higher. There are no other special requirements for administration. • Inform the patient of side effects and need for long-term monitoring before initiating treatment. • Provide information to the patient such as disease specific information and patient information sheets (e.g. from Macmillan). • Consent patient for this treatment and provide the patient with a carbon copy of the consent form. • Initiate treatment and prescribe hydroxycarbamide for a minimum of the first six weeks. • Monitor and establish safety and efficacy over the first three months of therapy. • Review patient in clinic. • Disease and drug monitoring as listed below, including hydroxycarbamide dose adjustments. • Inform the GP when they have initiated hydroxycarbamide • Specifically request GP via patient letters to add hydroxycarbamide to the repeat prescription list. To do this use the Shared Care Agreement Form which is available on consent / chart printing section of Pharmacy intranet pages. This shared care guideline must also be sent to the GP. The frequency of monitoring is determined by clinical need. At each appointment we test • Full blood count • Urea and electrolytes (including calcium and phosphate) • Liver function We would ensure the patients are monitored every 3 to 4 months. • To return the shared care agreement form promptly to the requesting clinician with the appropriate response. • Provide...
Dosage. Ovex: 1 tablet. If re-infection occurs, a second dose can be taken after 14 days. Advice and Follow up: • All other members of household over 2 years old should be treated simultaneously. • Hygiene measures should be taken for 14 days after treatment: Wash hands and scrub nails first thing every morning, after using the toilet or changing nappies, and immediately before eating (even snacks) or preparing food Have a bath or wash around the anus each morning immediately on rising Keep fingernails short Change and wash underwear, nightwear, soft toys and bed linen the morning after treatment Vacuum all carpets and clean bathroom surfaces daily Wear clean underwear daily Children should wear cotton underwear at night to help prevent scratching or spreading eggs and change underwear in the morning General Advice: • Avoidance of re-infection = personal hygiene Further self-care advice can be found at ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/conditions/threadworms/ Definition: Fungal yeast infection of the lower female genital tract. Presenting symptoms include thick, white or creamy vaginal discharge, external stinging or burning (pain) on urination with soreness and itching.
Dosage. The total number of family strengthening hours will be at least 4 b. High Need parents will participate in at least 1 family strengthening session per week c. Each family strengthening session will be a minimum of 1 hour d. The total number of health education and/or food security support will be a minimum of 1 hour OUTCOME - Protective Factors Survey (PFS) or Adult Adolescent Parenting Inventory (AAPI) The Protective Factors Survey measures increased family stability in the following domains: family functioning/parental resiliency; social connections; concrete support; social and emotional competence of children; and knowledge of parenting/child development. Administered twice: once at the start of services and once at a minimum of 4 hours of service. # of high need parents who start family strengthening Services 360 # of high need parents who receive at least 4 hours of family strengthening Services 180 # of high need parents who receive at least 1 hour of health education 276 # of high need parents who receive at least at least 1 hour of food security support 276 # of high need parents that receive 4 hours of family strengthening services will show a 20% increase in protective factors against child abuse as determined by pre/post PFS scores 144 # of high need parents that receive at least 1 hour of health education will demonstrate a 10% increase in health knowledge 216 # of high need parents that receive at least 1 hour of food support services will demonstrate a 10% increase in food security 216 Required Engage Community Volunteers in Service Target population is all community members with a particular focus on Parents of the beneficiary children.
Dosage. 1. 1 to a maximum of 4 immunizations; EPI schedule pre- ferred.
Dosage. Children: 10 mg/kg/dose every 4-6 hours, not to exceed 4 doses daily. Adults: 500-1000 mg per dose every 4-6 hours, not to exceed 4 g per day. Route: IV, oral, and rectal Nursing Administration Considerations: Give slowly over 15 minutes. Side Effects: Jaundice, leukopenia, signs of overdose are signs of liver failure. Drug Interactions: Increased bleeding time for patients on warfarin. (National Health Service, 2007) (Wolters Kluwer Health, 2009)